The Cardiac Contractility, Hypertrophy, and Failure (CCHF) Study Section reviews applications which propose basic, applied and translational studies for conditions that focus on contractile function, dysfunction and impact heart function, homeostasis and disease. Applications include studies of both hereditary and acquired cardiac hypertrophy and failure.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Cardiac hypertrophy and heart failure: Basic molecular and cellular mechanisms; myocyte growth, proliferation, metabolism and apoptosis; receptor signaling; transcriptional pathways; inflammatory/ cytokine-mediated processes.
- Systolic and diastolic function/dysfunction: adaptation to abnormal hemodynamic load and ventricular mechanics; mechanical signal transduction; stress-strain relationships; effects of therapeutic interventions such as pacing, ventricular assist devices and others; valvular heart disease.
- Myocardial remodeling and fibrosis: extracellular matrix reorganization and collagen metabolism; cytoskeleton.
- Cardiac myocyte contractile function: sarcomeric proteins; calcium regulation and signaling; calcium-force relationship; arrhythmia-related causes of remodeling and heart failure.
- Cardiac repair: addressing remodeling and contractility deficit that include cell-based, gene therapy and the evaluation of bioengineered cells and tissues; capillary density; changes in ventricular and cellular function that result from heart transplantation.
- Genetic cardiomyopathies: genotype-phenotype correlation; genomic and proteomic approaches to cardiac hypertrophy and failure.
Shared Interests and Overlaps
There are shared interests between CCHF and Myocardial Ischemia and Metabolism (MIM). While applications that focus on molecular and cellular mechanisms underlying cardiac hypertrophy or remodeling and heart failure may be reviewed in CCHF, these topics, in the context of diabetes and metabolic disorders, may be reviewed in MIM. Applications that focus on inherited cardiomyopathies that involve mitochondrial (dys)function may be reviewed in MIM. While stem cell therapy in the context of ischemic heart disease may be assigned to MIM, those that affect heart failure and impaired contractility may be reviewed in CCHF.
There are shared interests between CCHF and Cardiovascular Differentiation and Development (CDD). Developmental cardiac and valvular defects that lead to/account for heart failure or contractile dysfunction may be reviewed in CCHF. Applications that focus on the differentiation potential of stem cells, including naturally occurring developmental hypertrophy, even postnatally, may be reviewed in CDD.
There are shared interests between CCHF and Clinical and Integrative Cardiovascular Sciences (CICS): With topics related to heart failure and cardiomyopathy CICS may review applications that focus on clinical aspects of heart failure and cardiomyopathy in humans and human samples.
There are shared interests between CCHF and Electrical Signaling, Ion Transport and Arrhythmias (ESTA): Applications where impaired cardiac rhythm and cardiac arrhythmias contribute to cardiac dysfunction, hypertrophy and heart failure may be reviewed in CCHF.
There are shared interests between CCHF and Respiratory Integrative Biology and Translational Research (RIBT): While applications that generally focus on pulmonary conditions, including pulmonary hypertension, may be reviewed in RIBT; pulmonary conditions that affect cardiac contractile function, contribute to cardiac hypertrophy (right ventricular hypertrophy) and heart failure may be reviewed in CCHF.
There are shared interests between CCHF and Skeletal Muscle Biology and Exercise Physiology (SMEP): For applications that focus on contractile proteins and contractile systems in the context of cardiac contractile function, cardiac hypertrophy, and heart failure may be reviewed in CCHF; applications that focus on contractile function within the context of skeletal muscle may be assigned to SMEP.